title: Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms.
abstract: Aspirin's inhibitory effect on platelet function has been shown to be highly heterogeneous. However, due to the considerable individual variation in pharmacokinetics after aspirin intake, it has been difficult to investigate the mechanism of aspirin resistance empirically. Our objective was to examine whether platelet responsiveness to in vitro aspirin treatment could be affected by cyclooxygenase (COX)-1/2 protein levels in platelets or single-nucleotide polymorphisms (SNPs), which could possibly change specific activity of enzymes and/or aspirin susceptibility. Collagen/epinephrine closure time (CEPI-CT) of PFA-100 in blood from 178 healthy males was assessed with/without aspirin. Platelet COX-1 protein levels and the sequences of COX-1 gene exons were examined in three groups categorized by CEPI-CT: PR (Poor responders to aspirin), 10 people showing the shortest CEPI-CT under aspirin; GR-High or GR-Low (good responders to aspirin with high or low platelet basal reactivity), 10 people showing CEPI-CT over 300 s under aspirin and having the shortest or longest basal CEPI-CT, respectively. We analyzed the three groups, representing phenotypic extremes, aiming to increase statistical power to investigate the possible relevance of COXs to platelet response to aspirin. Western blot analysis revealed that COX-1 was abundantly expressed in platelets at comparable levels among the three groups, whereas COX-2 was undetectable. The frequencies of nonsynonymous COX-1/2 SNPs were unlikely to explain the difference in aspirin responsiveness considering the observed genotype frequencies and wide individual variation in platelet response. These results suggest that heterogeneity in platelet responsiveness to in vitro aspirin is independent of COX-1/2 protein levels and SNPs.
authors.affiliation: The Keio-Daiichi Project on Genetics of Thrombosis, Keio University, Tokyo 160-8582, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Miho
authors.initials: M
authors.lastname: Ushida
authors.forename: Risa
authors.initials: R
authors.lastname: Komine
authors.forename: Aya
authors.initials: A
authors.lastname: Shimodaira
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Uchida
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ishihara
authors.forename: Toshiro
authors.initials: T
authors.lastname: Shibano
authors.forename: Gentaro
authors.initials: G
authors.lastname: Watanabe
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Murata
mesh_terms: D000328:Adult; D001241:Aspirin / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects* / Q000201:enzymology; D051545:Cyclooxygenase 1 / Q000097:blood* / Q000235:genetics*; D051546:Cyclooxygenase 2 / Q000097:blood* / Q000235:genetics*; D005091:Exons; D006801:Humans; D007438:Introns; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide
chemical_list: D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D001241:Aspirin